Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct;12(4):283-90.
doi: 10.4103/0972-2327.58279.

Promising treatments of tomorrow for multiple sclerosis

Daniel M Harrison  1 , Peter A Calabresi
Affiliations

Promising treatments of tomorrow for multiple sclerosis

Daniel M Harrison et al. Ann Indian Acad Neurol. 2009 Oct.

Abstract

The therapeutic options for multiple sclerosis are rapidly expanding. What was once seen as a disease with little hope for treatment is now a target of rapid drug development. Current therapies have demonstrated efficacy in limiting the impact of the disease, but none is fully effective in all patients. However, promising new treatments are on the horizon. In this review we will discuss potential novel immunomodulating drugs that are in advanced stages of investigation; these drugs include monoclonal antibodies, chimeric molecules, and oral therapies. The use of hematopoietic stem cells will also be discussed and, in addition, we will look farther ahead at possible novel targets for the development of new immunomodulatory or neuroprotective pharmaceuticals.

Keywords: Drugs; investigational; multiple sclerosis; therapeutics.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Similar articles

See all similar articles

Cited by

References

    1. Sibley WA. the IFN-β Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655–61. - PubMed
    1. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III, multicenter, double-blind, placebo-controlled trial. Neurology. 1995;45:1268–76. - PubMed
    1. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: The Mutliple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol. 1996;39:285–94. - PubMed
    1. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomized study. Lancet. 2001;357:1576–82. - PubMed
    1. Barkhof F, Polman CH, Radue EW, Kappos L, Freedman MS, Edan G, et al. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: Integrated 2-year results. Arch Neurol. 2007:641292–8. - PubMed